Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel polymer micelles + gemcitabine + anlotinib
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of paclitaxel polymer micelles, gemcitabine, and anlotinib. Paclitaxel polymer micelles is a nanoparticle formulation of the taxane paclitaxel designed to improve solubility and reduce hypersensitivity reactions by avoiding Cremophor EL. Gemcitabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptors (PDGFR alpha and beta), and c-Kit. This combination is being investigated by Shanghai 6th People's Hospital as a second-line or later treatment for advanced soft tissue sarcomas to improve efficacy and reduce toxicity compared to standard chemotherapy.
- Other names
- MAGNATE-S regimen
02
Targets
DNA polymerase familyRET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on paclitaxel polymer micelles + gemcitabine + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel polymer micelles + gemcitabine + anlotinib.